IRCT201201318146N2
Completed
未知
Comparison of the efficacy and safety of Low-Fluence Q-Switched 1,064 nm Nd:YAG Laser and Low-Fluence CO2 Fractional Laser for treatment of melasma in patients referred to Shohada-e Tajrish hospital during 2012 :A Randomized Controlled Split-Face Study
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- melasma.
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •All patients suffering from melasma that referred for treatment in during 2012 to the shohada\-e tajrish treatment center form the study population.
- •Study inclusion criteria:
- •\-Age between 18 to 85 years old
- •\- Fitzpatrick skin type I\-V
- •\- symmetric distribution of melasma the in both sides of patient's face
- •study exclusion criteria:
- •\-usage of pigment reducing topical treatments 2 weeks prior to the study
- •\-usage of peeling agents 2 weeks prior to the study
- •\-laser therapy for melasma 1 month prior to the study
- •\-a history of poor wound healing, or abnormal scarring
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Study on the efficacy and safety of reduced-fluence photodynamic therapy for chronic central serous chorioretinopathychronic central serous chorioretinopathyJPRN-UMIN000008819Kawasaki Medical School Hospital Department of Ophthalmology10
Completed
Phase 3
osartan - Metoprolol XL Combination in Essential Hypertension Along with Type II DiabetesHealth Condition 1: null- Essential Hypertension Along with Type II DiabetesCTRI/2011/08/001937Ipca Laboratories Ltd158
Active, not recruiting
Phase 1
Exploratory study of the efficacy and safety of flexible doses of Milnacipran and Venlafaxine administered in out patients with Major Depressive Disorder.EUCTR2006-003658-47-FRPierre Fabre Médicament - IRPF180
Completed
Phase 3
Evaluation of Efficacy and Safety of Combination of Atorvastatin and Hydroxychloroquine with Atorvastatin alone in Patients with DyslipidemiaHealth Condition 1: null- primary dyslipidemiaCTRI/2010/091/006138Ipca Laboratories Ltd Mumbai328
Completed
Phase 3
Comparative study of the safety and efficacy of levofloxacin and ciprofloxacin in the treatment of community-acquired, bacterial urinary tract infection among patients with chronic kidney diseasePACTR202401622249032Dhikrullah Adebayo90